BusinessFrontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes: ResearchMozBy Nasdaq OMXSep 16, 2016, 11:05 AM UTC
